| Followers | 20 |
| Posts | 8382 |
| Boards Moderated | 5 |
| Alias Born | 10/17/2022 |
Wednesday, December 03, 2025 8:26:00 AM
$JUNS Analyst Report
Jupiter announced a partnership with Aquanova AG to develop a series of nutritional products targeting longevity, aging and healthspan. The first three products, which will focus on the concept of “Beauty from Within”, are slated to hit the market in Q3:25 through a Direct-to-Consumer model.
Investor Presentation https://www.redchip.com/stocks/JUNS
Jupiter announced a partnership with Aquanova AG to develop a series of nutritional products targeting longevity, aging and healthspan. The first three products, which will focus on the concept of “Beauty from Within”, are slated to hit the market in Q3:25 through a Direct-to-Consumer model.
Investor Presentation https://www.redchip.com/stocks/JUNS
Recent JUNS News
- Jupiter Neurosciences Announces Closing of $2.0 Million Registered Direct Offering • GlobeNewswire Inc. • 05/21/2026 09:15:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 05/21/2026 04:39:12 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 05/21/2026 01:54:45 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/21/2026 01:51:20 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/21/2026 12:14:07 PM
- Jupiter Neurosciences Announces Pricing of $2.0 Million Registered Direct Offering • GlobeNewswire Inc. • 05/20/2026 06:38:00 PM
- Micro-Cap Biotech Stocks Surge After Breakthrough Psychedelics Licensing Announcement • AllPennyStocks.com • 05/20/2026 03:35:00 PM
- PharmAla Biotech Signs Term Sheet for $100 Million U.S. Licensing Deal for ALA-002 MDMA Therapy (MDXXF) • IH Market News • 05/20/2026 03:12:27 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 05/20/2026 02:35:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/20/2026 01:45:15 PM
- PharmAla Biotech Signs Term Sheet to License Exclusive U.S. Rights to ALA-002, Its Next-Generation MDMA Therapeutic, to Jupiter Neurosciences, Inc. (NASDAQ: JUNS) in a Transaction Valued at Over $100 Million • GlobeNewswire Inc. • 05/20/2026 12:15:00 PM
- Jupiter Neurosciences Secures $100M Term Sheet for Exclusive U.S. Rights to ALA-002, a Next-Generation MDMA Therapeutic from PharmAla Biotech • GlobeNewswire Inc. • 05/20/2026 11:38:00 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 05/14/2026 09:20:53 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/14/2026 09:00:54 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 05/08/2026 08:05:22 PM
- Jupiter Neurosciences, Inc. to Present at The Market Movers Investor Summit • Newsfile • 05/04/2026 03:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/27/2026 04:15:16 AM
- Jupiter Neurosciences, Inc. to Present at Centri Capital Conference on April 14 • Newsfile • 04/14/2026 12:00:00 AM
- Jupiter Neurosciences Appoints Kristopher Fishman and Sanjiv Lal to Nugevia™ Advisory Board • GlobeNewswire Inc. • 04/07/2026 12:00:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 04/01/2026 08:45:31 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 04/01/2026 08:38:05 PM
- Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing • GlobeNewswire Inc. • 03/13/2026 12:35:00 PM
- Life Sciences Virtual Investor Forum Agenda Announced for March 11th & 12th • GlobeNewswire Inc. • 03/10/2026 02:21:44 PM
- Jupiter Neurosciences to Present at BIO Investment and Growth Summit 2026 • GlobeNewswire Inc. • 03/02/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/27/2026 09:30:55 PM
